Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Pazopanib in Advanced Renal Cell Carcinoma
NCT02014636Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2013
- Primary completion
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of pembrolizumab in renal cell carcinoma (RCC) (4 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Dose limiting toxicity and maximum tolerated regimen at 8 weeks and 6 more. Started Dec 2013; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02014636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014636.